291 Campus Drive
Stanford, CA 94305
“Whole Genome Sequencing of Bronchodilator Response in Minority Children with Asthma”
Event and Registration Information.
Asthma is a chronic inflammatory disorder of the airways characterized by recurrent respiratory symptoms and reversible airway obstruction. Asthma affects 5% of the world population and is one of the most common chronic diseases among children. In the U.S., asthma prevalence is highest among Puerto Ricans (36.5%), intermediate among African Americans (13.0%) and European Americans (12.1%), and lowest among Mexican Americans (7.5%). These disparities also extend to asthma mortality, which is four-fold higher in Puerto Ricans and African Americans compared to European and Mexican Americans. Albuterol, a bronchodilator medication, is the first-line therapy for asthma treatment worldwide, despite a wide variation of drug response among different racial/ethnic groups.
We performed the largest pharmacogenetics study of albuterol response to date, using whole genome sequencing data from 1,441 minority children with asthma from the extremes of bronchodilator (albuterol) drug response distribution.
Our study expands the understanding of pharmacogenetic analyses in racially and ethnically diverse populations and advances the foundation for precision medicine in at-risk and understudied minority populations.